Biologics and immunotherapyAnti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
Key words
Abbreviations used
Cited by (0)
This indirect treatment comparison was funded by GlaxoSmithKline (GSK ID no. 209020/HO-18-19164). GlaxoSmithKline had a role in the design of the analysis, data collection, data analysis, and data interpretation. The funder did not place any restrictions on access to the data or statements made in the manuscript. The decision to submit for publication was that of the authors alone.
Disclosure of potential conflict of interest: W. Busse reports personal fees from Novartis, AstraZeneca, GlaxoSmithKline, Genentech, Regeneron, Sanofi, Boston Scientific, and ICON Clinical Research; royalties from Elsevier; and grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the NIH/National Heart, Lung, and Blood Institute (NHLBI). G. Chupp has acted as a consultant, for AstraZeneca, Genentech, Boehringer Ingelheim, and Teva; attended a speakers' bureau with AstraZeneca, Genentech, and Circassia; and received research grants from AstraZeneca and institutional grants from AstraZeneca, Genentech, Boehringer Ingelheim, and GlaxoSmithKline. H. Nagase has attended advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis and received speaker's fees from AstraZeneca, Boehringer Ingelheim, Kyorin Pharmaceutical, and Novartis. F. C. Albers, S. Doyle, Q. Shen, D. J. Bratton, and N. B. Gunsoy are employees of and hold stocks/shares in GlaxoSmithKline.